Anticancer Res. 1999 Nov-Dec;19(6B):5355-60.
Slade N, Storga-Tomic D, Birkmayer GD, Pavelic K, Pavelic J.
Subscribe to the World's Most Popular Newsletter (it's free!)
Division of Molecular Medicine, Ruder Boskovic Institute, Zagreb, Croatia.
We investigated the antiproliferative effects of extracellular nicotinamide adenine dinucleotide against human malignant CaCo-2 (colon carcinoma), Hep-2 (laryngeal carcinoma), MCF-7 (breast carcinoma), CaSki (cervix carcinoma) cell lines, as well as against murine fibrosarcoma and normal human embryonal fibroblast (HEF).
NADH was very potent in the growth inhibition of murine fibrosarcoma and human Hep-2 cells, regardless of the dose applied. During the observed period (4 or 5 days) only one dose of NADH was sufficient in reducing the growth rate for up to 92%. It had no effect on the growth of other cell lines tested. The identification of DNA-fragmentation and p53 and Ki-67 genes expression suggest that the mechanism of NADH action is different from disregulation of genes considered as check-points in cell cycle.
PMID: 10697561 [PubMed – indexed for MEDLINE]